For US Healthcare Professionals Only

Why biorphen?

FDA-approved, ready-to-use Biorphen can be quickly and conveniently administered without compounding.¹ Prepare Biorphen and adjust dosing to patient requirements.

BENEFITS OF BIORPHEN

3-year shelf life²

No compounding¹ *

Standardized across hospital

Administered by any trained staff without compounding*

Sulfite and preservative free

*Prepare Biorphen and adjust dosing to patient requirements.

BIORPHEN VS COMPOUNDED PHENYLEPHRINE

Features	RTU Biorphen	Compounded phenylephrine
FDA-approved drug
No compounding or dilution¹ *
3-year shelf life²
Standardized RTU concentration

*Prepare Biorphen and adjust dosing to patient requirements.

ASHP GUIDELINES

Biorphen meets certain risk-reduction strategies outlined in American Society of Health-System Pharmacists (ASHP) Guidelines for Preventing Medication Errors in Hospitals,³ including:

Standardizing concentration
Using commercially available products instead of compounding
Dispensing oral and parenteral medications in the most ready-to-administer form

Are you ready to adopt Biorphen?

References:

Biorphen [Package Insert]. Deer Park, IL: Eton Pharmaceuticals Inc; 2019.
Biorphen data on file. Deer Park, IL: Eton Pharmaceuticals Inc; 2019.
American Society of Health-System Pharmacists. ASHP guidelines on preventing medication errors in hospitals. Am J Health-Syst Pharm. 2018;75:1493–1517.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

None

WARNINGS AND PRECAUTIONS

Biorphen^® can precipitate angina in patients with severe arteriosclerosis or history of angina, exacerbate underlying heart failure, and increase pulmonary arterial pressure. Can also cause excessive peripheral and visceral vasoconstriction and ischemia to vital organs. Extravasation during intravenous administration may cause necrosis or sloughing of tissue. Can cause severe bradycardia and decreased cardiac output, renal toxicity, augmented pressor effect in patients with autonomic dysfunction, and pressor effect with concomitant oxytocic drugs.

ADVERSE REACTIONS

Most common adverse reactions during treatment: nausea, vomiting, and headache.

To report SUSPECTED ADVERSE REACTIONS, contact Eton Pharmaceuticals, Inc. at 1-888-450-0568 or FDA at 1-800-FDA-1088.

DRUG INTERACTIONS

Agonistic Effects (increase in Biorphen blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids.
Antagonistic Effects (decrease in Biorphen blood pressure effect) can occur with α-adrenergic antagonists, phosphodiesterase Type 5 inhibitors, mixed α- and β-receptor antagonists, calcium channel blockers, benzodiazepines and ACE inhibitors, centrally acting sympatholytic agents.

OVERDOSAGE

Overdose of Biorphen (phenylephrine hydrochloride) can cause a rapid rise in blood pressure. Symptoms of overdose include headache, vomiting, hypertension, reflex bradycardia, a sensation of fullness in the head, tingling of the extremities, and cardiac arrhythmias including ventricular extrasystoles and ventricular tachycardia.

For more information, please see Biorphen Full Prescribing Information.

Indications and Usage

Biorphen (phenylephrine hydrochloride) injection 100 mcg/mL is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia.

All contents copyright 2021 by Eton Pharmaceuticals, Inc. All rights reserved. All trademarks are the property of their respective owners. WS-202-001-rev5-04/21